✦ LIBER ✦

`Maxamine' plus IL-2 shows promise in malignant melanoma

Book ID: 120870169
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 138 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012370-00018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Temozolomide plus thalidomide promising

Temozolomide plus thalidomide promising in malignant melanoma

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 120 KB

Azacitdine plus phenylbutyrate shows pro

Azacitdine plus phenylbutyrate shows promise in myeloid malignancies

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

IL-2 in the therapy of melanoma and othe

IL-2 in the therapy of melanoma and other malignancies

✍ Kim Margolin 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 211 KB

Study of IL-2 receptor expression after

Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma

✍ R. MOUAWAD; M. ICHEN; O. RIXE; A. BENHAMMOUDA; E. VUILLEMIN; M. WEIL; D. KHAYAT; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB

Phase 2 trial of combination thalidomide

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

✍ Joseph I. Clark; James Moon; Laura F. Hutchins; Jeffrey A. Sosman; W. Martin Kas 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Sequential therapy with IFN-α-2b plus al

Sequential therapy with IFN-α-2b plus aldesleukin and fotemustine: `efficient' option in stage IV malignant melanoma?

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB